Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Finance - Asia Logue

The Latest: Hammond says Britain a good Belt & Road partner

Apr 26, 2019

BEIJING — The Latest on China's Belt and Road infrastructure building conference. (all times local): 8:00 p.m. British treasury chief Philip Hammond says Britain's finance industry would be a "natural partner" for future projects under China's Belt and Road infrastructure initiative. On the sidelines of a Belt and Road forum in Beijing Friday, Hammond did not directly say whether Britain was considering signing an agreement to support the initiative, as Italy did last month. But he said that if future projects were held to the highest standards "there is a potential important future partnership there for us." Chinese President Xi...

World shares mostly dip on earnings, ahead of US growth data

Apr 26, 2019

BANGKOK — Global stock markets mostly edged lower on Friday amid weak corporate news and ahead of the release of U.S. economic growth data later in the day. After losses in much of Asia, Britain's FTSE 100 fell 0.2% to 7,420, though Germany's DAX eked out a 0.1% gain to 12,300. The CAC40 in Paris was roughly flat at 5,560. Wall Street looked set for a weak open, with the future contract for the Dow down 0.1% and that for the S&P 500 off less than 0.1%. Corporate news has been mixed, with carmaker Daimler reporting a drop in earnings...

Putin lauds China infrastructure initiative, warming ties

Apr 26, 2019

BEIJING — Russian President Vladimir Putin praised China's Belt and Road infrastructure initiative Friday, underscoring warming ties between the neighboring powers. Putin's comments Friday to a forum in Beijing appeared to downplay the potential for tensions between China and Russia. They also reflect Beijing and Moscow's shared resistance to U.S. global influence. The Belt and Road is rapidly expanding China's economic footprint in Central Asia, Moscow's traditional sphere of influence. But in an interview published Thursday remarking on 70 years of diplomatic relations, Putin praised Russia-China ties. "It would be no exaggeration to say that our countries have approached this...

Asian shares fall on China stimulus worries, weak earnings

Apr 26, 2019

BANGKOK — Shares were mostly lower in Asia on Friday after an overnight decline on Wall Street spurred by disappointingly weak earnings reports from 3M and other industrial companies. Concern that China may temper its economic stimulus pulled the Shanghai benchmark down 0.8% to 3,099.36. Japan's Nikkei 225 index slipped 0.5% to 22,193.41 and the Kospi in South Korea declined 0.6% to 2,175.89. Australia's S&P ASX 200 edged 0.1% higher to 6,388.20 while the Hang Seng in Hong Kong added 9.33 points to 29,564.49. Shares fell in Taiwan and Singapore but rose in Jakarta. Traders are watching for U.S. growth...

China's Xi promotes building initiative amid debt worries

Apr 26, 2019

BEIJING — President Xi Jinping promised Friday to promote high financial standards for China's infrastructure-building initiative as Beijing tries to dispel complaints the multibillion-dollar program leaves developing countries with too much debt. Xi avoided mentioning debt in a speech at the opening of a Belt and Road forum attended by leaders of three dozen countries to celebrate his signature foreign initiative. But he said Beijing wants "open, green and clean cooperation" with "zero tolerance for corruption." Developing countries welcome the initiative to expand trade by building roads, ports and other facilities across a vast arc of countries from Asia through...

Sign up now!

Advertisement